SuperworthCytokinetics shares outstanding CYTK
Diluted shares outstanding, averaged over each quarter, from 2010.
- Latest quarter, to Jun 30, 2026
- 132.1M
- On a year earlier
- +10.6%
- more shares
Cytokinetics had 132.1M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 10.6% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 122.4M | +4% |
| FY2024 | 118.1M | +19% |
| FY2023 | 99.1M | +5% |
| FY2022 | 94.7M | +13% |
| FY2021 | 84.1M | +19% |
| FY2020 | 70.8M | +20% |
| FY2019 | 59.1M | +8% |
| FY2018 | 54.7M | +1% |
| FY2017 | 53.9M | +24% |
| FY2016 | 43.5M | +11% |
| FY2015 | 39.1M | +6% |
| FY2014 | 36.7M | +23% |
| FY2013 | 29.8M | +26% |
| FY2012 | 23.7M | +96% |
| FY2011 | 12.1M | +10% |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 132.1M | +11% | |
| Q1 FY26 | 123.3M | +4% | |
| Q4 FY25 | 122.4M | +4% | |
| Q3 FY25 | 120M | +2% | |
| Q2 FY25 | 119.5M | +9% | |
| Q1 FY25 | 118.5M | +16% | |
| Q4 FY24 | 118.1M | +19% | |
| Q3 FY24 | 117.7M | +22% | |
| Q2 FY24 | 109.2M | +14% | |
| Q1 FY24 | 101.9M | +7% | |
| Q4 FY23 | 99.1M | +5% | |
| Q3 FY23 | 96.1M | +2% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Cytokinetics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.